What is the price range for Canafenib/Encofenib reimbursed by medical insurance?

Encorafenib is one of the BRAF inhibitors that has attracted much attention in the field of global tumor targeted therapy in recent years. The drug was officially approved for marketing in China on June 30, 2025, marking that domestic patients have more treatment options in the targeted treatment of BRAF V600E mutation-related malignant tumors such as melanoma and colorectal cancer. However, the medical insurance reimbursement price and related policies of Encofenib are still at an unknown stage. The main reason is that it has been on the market for a short time and has not yet completed the dynamic adjustment of the national medical insurance catalog and the implementation of local medical insurance policies.

As of now, the official price of Encofenib in the Chinese market has not been announced, so patients and medical institutions have certain fluctuations in their price expectations. According to experience in overseas markets, the price of the original Canafenib drug is relatively high. For example, the price of a single box in the European and American markets is generally more than tens of thousands of yuan, which also affects its bargaining space in domestic medical insurance negotiations. Updates to China's medical insurance catalog usually rely on the clinical value assessment of drugs, economic analysis and the results of price negotiations with pharmaceutical companies. Therefore, the specific reimbursement ratio and price range for Encofenib to enter the medical insurance will depend on the progress of future negotiations on the medical insurance directory.

Currently, if patients want to use Encofenib as soon as possible, they can obtain it through regular overseas drug procurement channels. The overseas version is mostly sold in the specification of 75mg, and the packaging is diversified to facilitate different treatment cycle needs. However, it is necessary to pay attention to the import procedures, drug safety and connection issues with domestic medical supervision involved in purchasing drugs overseas. At the same time, generic drug manufacturers in Laos and other places have launched generic canafenib drugs with basically the same ingredients and relatively low prices. However, they have not yet been formally approved in China, and the risks should be carefully weighed when using them.

Reference materials:https://www.braftovi.com/